Physitrack Q4 2024: Topline beat - Redeye

Redeye shares its initial take on Physitrack’s Q4 results, which came in above our expectations in terms of the top line. Lifecare continued its solid growth trajectory, contributing to an overall organic growth of 14% y/y. The Wellness division showed signs of recovery, posting a 13% y/y increase, though previous rollout delays remained a headwind. Highlights included sustained ARR growth at 17% y/y, stronger-than-expected topline performance and positive FCF. However, higher-than-anticipated costs weighed on margins. We expect to make minor adjustments to our estimates and fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1084369/physitrack-q4-2024-topline-beat?utm_source=finwire&utm_medium=RSS